608 related articles for article (PubMed ID: 25754881)
1. Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease.
Babu KS; Morjaria JB
Ther Adv Respir Dis; 2015 Apr; 9(2):56-68. PubMed ID: 25754881
[TBL] [Abstract][Full Text] [Related]
2. New opportunities of dual bronchodilation therapy for patients with chronic obstructive pulmonary disease.
Avdeev SN; Trushenko NV
Ter Arkh; 2019 Mar; 91(3):76-85. PubMed ID: 31094464
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
D'Urzo AD; Rennard SI; Kerwin EM; Mergel V; Leselbaum AR; Caracta CF;
Respir Res; 2014 Oct; 15(1):123. PubMed ID: 25756831
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
Ridolo E; Montagni M; Riario-Sforza GG; Baroni M; Incorvaia C
Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
[TBL] [Abstract][Full Text] [Related]
5. Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease.
D'Urzo T; Donohue JF; Price D; Miravitlles M; Kerwin E
Expert Rev Respir Med; 2015 Oct; 9(5):519-32. PubMed ID: 26366803
[TBL] [Abstract][Full Text] [Related]
6. Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives.
Rhee CK; Yoshisue H; Lad R
Adv Ther; 2019 Mar; 36(3):495-519. PubMed ID: 30742242
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT.
D'Urzo AD; Singh D; Donohue JF; Kerwin EM; Ribera A; Molins E; Chuecos F; Jarreta D; Gil EG
Int J Chron Obstruct Pulmon Dis; 2019; 14():479-491. PubMed ID: 30880938
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis.
Miravitlles M; Chapman KR; Chuecos F; Ribera A; Gil EG
Int J Chron Obstruct Pulmon Dis; 2016; 11():2041-53. PubMed ID: 27621610
[TBL] [Abstract][Full Text] [Related]
9. Aclidinium bromide and formoterol fumarate for the maintenance treatment of chronic obstructive pulmonary disease.
Haley R; Gupta N; Sethi S
Expert Rev Clin Pharmacol; 2020 Feb; 13(2):103-113. PubMed ID: 31951778
[No Abstract] [Full Text] [Related]
10. Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies.
Martinez FJ; Rabe KF; Lipworth BJ; Arora S; Jenkins M; Martin UJ; Reisner C
Int J Chron Obstruct Pulmon Dis; 2020; 15():99-106. PubMed ID: 32021148
[TBL] [Abstract][Full Text] [Related]
11. Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease.
Cazzola M; Rogliani P; Matera MG
Expert Opin Pharmacother; 2013 Apr; 14(6):775-81. PubMed ID: 23472632
[TBL] [Abstract][Full Text] [Related]
12. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
Singh D; D'Urzo AD; Chuecos F; Muñoz A; Garcia Gil E
Respir Res; 2017 May; 18(1):106. PubMed ID: 28558833
[TBL] [Abstract][Full Text] [Related]
13. Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD--role of umeclidinium/vilanterol.
Malerba M; Morjaria JB; Radaeli A
Int J Chron Obstruct Pulmon Dis; 2014; 9():687-95. PubMed ID: 25061288
[TBL] [Abstract][Full Text] [Related]
14. AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD.
Sethi S; Kerwin E; Watz H; Ferguson GT; Mroz RM; Segarra R; Molins E; Jarreta D; Garcia Gil E
Int J Chron Obstruct Pulmon Dis; 2019; 14():667-682. PubMed ID: 30962681
[TBL] [Abstract][Full Text] [Related]
15. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.
Singh D; Corradi M; Spinola M; Papi A; Usmani OS; Scuri M; Petruzzelli S; Vestbo J
Int J Chron Obstruct Pulmon Dis; 2017; 12():2917-2928. PubMed ID: 29062229
[TBL] [Abstract][Full Text] [Related]
16. Symptom variability and control in COPD: Advantages of dual bronchodilation therapy.
Di Marco F; Santus P; Scichilone N; Solidoro P; Contoli M; Braido F; Corsico AG
Respir Med; 2017 Apr; 125():49-56. PubMed ID: 28340862
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Aclidinium/Formoterol versus Tiotropium in COPD: Results of an Indirect Treatment Comparison.
Medic G; Lindner L; van der Weijden M; Karabis A
Adv Ther; 2016 Mar; 33(3):379-99. PubMed ID: 26883661
[TBL] [Abstract][Full Text] [Related]
18. Glycopyrrolate/formoterol (Bevespi Aerosphere) for COPD.
Med Lett Drugs Ther; 2016 Oct; 58(1505):130-132. PubMed ID: 27701364
[No Abstract] [Full Text] [Related]
19. Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD.
Donohue JF; Soong W; Wu X; Shrestha P; Lei A
Respir Med; 2016 Jul; 116():41-8. PubMed ID: 27296819
[TBL] [Abstract][Full Text] [Related]
20. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD.
Watz H; Troosters T; Beeh KM; Garcia-Aymerich J; Paggiaro P; Molins E; Notari M; Zapata A; Jarreta D; Garcia Gil E
Int J Chron Obstruct Pulmon Dis; 2017; 12():2545-2558. PubMed ID: 28883722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
